Results 71 to 80 of about 1,848 (184)

Invasive Management for Acute‐on‐Chronic Thromboembolic Pulmonary Hypertension: Feasibility and Clinical Outcomes in a Single‐Center Cohort

Pulmonary Circulation, Volume 16, Issue 3, July 2026.
In this single‐center cohort of 15 critically ill patients with acute‐on‐chronic thromboembolic pulmonary hypertension, invasive management with pulmonary endarterectomy and/or balloon pulmonary angioplasty was associated with substantial hemodynamic improvement.
Jun Yamashita, Ryosuke Ito, Sayo Ikeda, Koki Hasegawa, Yoshikazu Takeuchi, Tomohiro Kasahara, Naotaka Murata, Shun Suzuki, Hideaki Kanazawa, Yusuke Shimahara, Kazuhiro Satomi   +10 more
wiley   +1 more source

Rescue Balloon Pulmonary Angioplasty Prior to Pulmonary Endarterectomy With Concomitant Mitral Valve Plasty in High‐Risk Operable CTEPH

Pulmonary Circulation, Volume 16, Issue 2, April 2026.
ABSTRACT Pulmonary endarterectomy (PEA) is a potentially curative treatment for chronic thromboembolic pulmonary hypertension (CTEPH); however, decompensated right heart failure and concomitant cardiac procedures increase the risk of postoperative mortality. We report a case of operable CTEPH with severe mitral regurgitation causing right heart failure
Keiichi Ishida, Nobutaka Ikeda, Seiichiro Sakao, Koichiro Sugimura, Ryuki Yamada, Norihisa Yuge, Susumu Manabe   +6 more
wiley   +1 more source

Challenges and Strategies in Managing Pulmonary Arterial Hypertension Within the Indian Healthcare System: A Consensus Statement From the Pulmonary Vascular Research Institute India Taskforce

Pulmonary Circulation, Volume 16, Issue 2, April 2026.
ABSTRACT Pulmonary arterial hypertension (PAH) in India is a substantial yet under‐recognized contributor to cardiovascular morbidity and mortality. Its progressive course, nonspecific early manifestations, and heterogeneous aetiologies often lead to delayed diagnosis and fragmented care.
Prashant Bobhate, Neeraj Awasthy, Abraham Samuel Babu, Shatabdi Giri, Arun Gopalakrishnan, Sivadasanpillai Harikrishnan, Niharikar Karandikar, Basha J. Khan, Snehal Kulkarni, Shine Kumar, Rahul Mehrotra, Smrutiranjan Mohanty, S. Ramakrishnan, Anita Saxena, Padmanabha Shenoy, B. K. Srinivasa Sastry, T. Sunder   +16 more
wiley   +1 more source

Transition from selexipag to oral treprostinil in a patient with pulmonary arterial hypertension

Pulmonary Circulation, 2020
Prostacyclins are the mainstay treatment for patients with severe pulmonary arterial hypertension. This case highlights the transition from selexipag to oral treprostinil. Our patient improved both subjectively and objectively.
Ifeoma Oriaku, Amol Patel, Zeenat Safdar
doaj   +1 more source

Nanosuspensions of Selexipag: Formulation, Characterization, and in vitro Evaluation

, 2021
Selexipag is an orally selective long-acting prostacyclin receptor agonist, which indicated for the treatment of pulmonary arterial hypertension. It is practically insoluble in water ( class II, according to BCS).
Rusul M. Alwan, Nawal A. Rajab
core   +1 more source

Real-life data on Selexipag for the treatment of pulmonary hypertension

Pulmonary Circulation, 2019
Selexipag is an orally available selective IP prostacyclin-receptor agonist licensed since 2016 for the therapy of pulmonary arterial hypertension (PAH).
Michaela Barnikel, Nikolaus Kneidinger, Friederike Klenner, Andrea Waelde, Paola Arnold, Torben Sonneck, Jürgen Behr, Claus Neurohr, Katrin Milger   +8 more
doaj   +1 more source

Selexipag, an oral, selective IP receptor agonist for the treatment of pulmonary arterial hypertension

, 2012
In this phase 2 proof-of-concept study we examined the safety and efficacy of selexipag, an orally available, selective prostacyclin receptor (IP receptor) agonist, as a treatment for pulmonary arterial hypertension (PAH).
Simonneau G, Torbicki A, Hoeper MM, Bonderman D, Efficace M, Karlócai K, Lang IM, Degano B, Giorgino R, Delcroix M, GALIE', NAZZARENO, Kurzyna M   +11 more
core   +1 more source

Switching from Beraprost to Selexipag in the Treatment of Pulmonary Arterial Hypertension: Insights from a Phase IV Study of the Japanese Registry (The EXCEL Study: EXChange from bEraprost to seLexipag Study)

Pharmaceuticals
Pulmonary arterial hypertension (PAH) remains a significant challenge in cardiology, necessitating advancements in treatment strategies. This study explores the safety and efficacy of transitioning patients from beraprost to selexipag, a novel selective ...
Yuichi Tamura, Hiraku Kumamaru, Ichizo Tsujino, Rika Suda, Kohtaro Abe, Takumi Inami, Koshin Horimoto, Shiro Adachi, Satoshi Yasuda, Fusako Sera, Yu Taniguchi, Masataka Kuwana, Koichiro Tatsumi   +12 more
doaj   +1 more source

PREPARATION AND CHARACTERIZATION OF SOLID DISPERSION LOADED WITH SELEXIPAG AS MODEL DRUG

Objective: The study aims to prepare solid dispersions of selexipag to enhance its aqueous solubility using two different techniques—solvent evaporation and kneading.
ABDUL-HASAN, MAZIN THAMIR, KARAM, DOAA HUSSEIN   +1 more
core   +2 more sources

Effects of macitentan and selexipag across prognostic age groups in patients with pulmonary arterial hypertension

JHLT Open
BACKGROUND: Age affects disease severity and patient outcomes in pulmonary arterial hypertension. This post-hoc analysis identified prognostic age groups and associated macitentan/selexipag treatment effects.
Richard Channick, MD, Sarah Medrek, MD, Marion Delcroix, MD, Sean Gaine, MD, Pavel Jansa, MD, PhD, Irene Lang, MD, Vallerie McLaughlin, MD, Sanjay Mehta, MD, Tomas Pulido, MD, Bhagavatula Sastry, MD, Rogerio Souza, MD, PhD, Adam Torbicki, MD, Carol Zhao, MS, Paul Strachan, MD, Peter Agron, PhD, Joseph Yen, PhD, Olivier Sitbon, MD, PhD   +16 more
doaj   +1 more source